ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Constant Therapeutics Announces Start of Phase 2 Trial of Peptide Drug TXA127 for COVID-19
August 06, 2020Constant Therapeutics announced its peptide drug TXA127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7), will be tested in a Phase 2 clinical trial at Columbia University Irving Medical Center in New York, New York. -
TXA127 enters multiple Phase II trials in COVID-19 patients
July 14, 2020A pharmaceutical formulation of the human angiotensin peptide, TXA127, will enter Phase II trials in hospitalised COVID-19 patients not in intensive care.
Pharma Sources Insight January 2025
